Erasca, Inc.
ERAS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001761918
No open-market purchases or sales by Erasca, Inc. insiders were filed in the last 90 days; 256 institutions reported holding it in 13F filings for Q2 2026, worth $5.13B in total; no superinvestor holds it.
Q1 2022 vs. Q4 2021
How the institutions holding Erasca, Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 63 | 82 | +19 |
| Shares | 63.7M | 72.8M | +9.15M (+14.4%) |
| Value | $988.0M | $626.6M | −$361.4M (−36.6%) |
New holders (26)
Institutions that held Erasca, Inc. at the end of Q1 2022 but not at the end of Q4 2021.
Sold out (7)
Institutions that held Erasca, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| HHLR Advisors, Ltd.SuperinvestorHHLR Advisors (Hillhouse) | 4,722,221 | $73.6M |
| Ghisallo Capital Management LLC | 30,000 | $467.0K |
| Tudor Investment Corp Et Al | 15,794 | $246.0K |
| Ergoteles LLC | 13,338 | $208.0K |
| UBS Group AG | 7,529 | $118.0K |
| Exane Derivatives | 5,589 | $87.1K |
| High Net Worth Advisory Group LLC | 200 | $3.00K |